Leerink Partners analyst Richard Newitter maintained a Buy rating on Inspire Medical Systems (NYSE:INSP) on Wednesday, setting a price target of $265, which is approximately 41.71% above the present share price of $187.
Newitter expects Inspire Medical Systems to post earnings per share (EPS) of -$0.60 for the third quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Inspire Medical Systems, with an average price target of $256.6.
The analysts price targets range from a high of $265 to a low of $238.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $40.35 million and a net profit of -$15.69 million. The company's market cap is $5.09 billion.
According to TipRanks.com, Leerink Partners analyst Richard Newitter is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 24.0% and a 66.14% success rate.
Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.